Loading…

Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway

Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to inves...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical and experimental pathology 2014-01, Vol.7 (10), p.6626-6634
Main Authors: Zhang, Sainan, Yang, Naibin, Ni, Shunlan, Li, Wenyuan, Xu, Lanman, Dong, Peihong, Lu, Mingqin
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 6634
container_issue 10
container_start_page 6626
container_title International journal of clinical and experimental pathology
container_volume 7
creator Zhang, Sainan
Yang, Naibin
Ni, Shunlan
Li, Wenyuan
Xu, Lanman
Dong, Peihong
Lu, Mingqin
description Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to investigate the protecting mechanisms of endotoxin tolerance in acute liver failure induced by D-galactosamine (D-GalN)/LPS and possible role of toll-like receptors 4 (TLR4) signaling pathway in this phenomenon. Acute liver failure was induced by Injection of D-GalN/LPS. To mimic endotoxin tolerance, male Sprague-Dawley rats were treated with low dose of LPS (0.1 mg/kg once a day intraperitoneally for consecutive five days) before subsequent injection of D-GalN/LPS. Rat survival was determined by survival rate. Liver injury was confirmed by serum biochemical and liver histopathological examination. Inflammatory cytokines were determined by ELISA and nuclear factor-kappa B (NF-κB) (P65), toll-like receptors 4 (TLR4) and Interleukin-1 receptor-associated kinase-1 (IRAK-1) were measured by reverse transcriptase polymerase chain reaction and western blot respectively. Pretreatment of LPS significantly improved rat survival. Moreover, rats pretreated with LPS exhibited lower serum enzyme (ALT, AST and TBiL) level, lower production of inflammatory cytokines and more minor liver histopathological damage than rats without pretreatment of LPS. LPS pretreatment suppressed production of TLR4 and IRAK-1. LPS pretreatment also inhibited activation of hepatic NF-κB. These results indicated that endotoxin tolerance contributed to liver protection against D-GalN/LPS induced acute liver failure through down-regulation of TLR4 and NF-κB pathway.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1627076699</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-5a5de247d23ecc7b09b84264bcddfda70a13432e0288551fab06082d08e157ba3</originalsourceid><addsrcrecordid>eNpVkFtLxDAQhYsgul7-guRRH4ppmqbdF0HWKyy66Ppcpsm0jaRNTdKV9ddb8II-DZyZ-Q7n7ESzZJ6KmAmW7UcH3r9SKhLG6V60zzJOac6TWfSxchgcQuiwD8TWxOjBDtZsPUjZgtMKyely9XxGoEOjrYOAnlzFt2Aezied6F6NEhUBOQacvjfoSA3ajA5JaJ0dm5asl0-ceN30YHTfkAFC-w7bo2i3BuPx-HseRi831-vFXbx8vL1fXC7jgQkR4gwyhYzniqUoZV7ReVVwJngllaoV5BSSlKcMKSuKLEtqqKigBVO0wCTLK0gPo4sv7jBWHSo5BXVgysHpDty2tKDL_5tet2VjNyVn6dRSNgFOvwHOvo3oQ9lpL9EY6NGOvkwEy2kuxHw-nZ789fo1-Sk8_QQYvn38</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1627076699</pqid></control><display><type>article</type><title>Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway</title><source>PubMed Central Free</source><creator>Zhang, Sainan ; Yang, Naibin ; Ni, Shunlan ; Li, Wenyuan ; Xu, Lanman ; Dong, Peihong ; Lu, Mingqin</creator><creatorcontrib>Zhang, Sainan ; Yang, Naibin ; Ni, Shunlan ; Li, Wenyuan ; Xu, Lanman ; Dong, Peihong ; Lu, Mingqin</creatorcontrib><description>Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to investigate the protecting mechanisms of endotoxin tolerance in acute liver failure induced by D-galactosamine (D-GalN)/LPS and possible role of toll-like receptors 4 (TLR4) signaling pathway in this phenomenon. Acute liver failure was induced by Injection of D-GalN/LPS. To mimic endotoxin tolerance, male Sprague-Dawley rats were treated with low dose of LPS (0.1 mg/kg once a day intraperitoneally for consecutive five days) before subsequent injection of D-GalN/LPS. Rat survival was determined by survival rate. Liver injury was confirmed by serum biochemical and liver histopathological examination. Inflammatory cytokines were determined by ELISA and nuclear factor-kappa B (NF-κB) (P65), toll-like receptors 4 (TLR4) and Interleukin-1 receptor-associated kinase-1 (IRAK-1) were measured by reverse transcriptase polymerase chain reaction and western blot respectively. Pretreatment of LPS significantly improved rat survival. Moreover, rats pretreated with LPS exhibited lower serum enzyme (ALT, AST and TBiL) level, lower production of inflammatory cytokines and more minor liver histopathological damage than rats without pretreatment of LPS. LPS pretreatment suppressed production of TLR4 and IRAK-1. LPS pretreatment also inhibited activation of hepatic NF-κB. These results indicated that endotoxin tolerance contributed to liver protection against D-GalN/LPS induced acute liver failure through down-regulation of TLR4 and NF-κB pathway.</description><identifier>EISSN: 1936-2625</identifier><identifier>PMID: 25400741</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Animals ; Chemical and Drug Induced Liver Injury - etiology ; Chemical and Drug Induced Liver Injury - immunology ; Chemical and Drug Induced Liver Injury - metabolism ; Chemical and Drug Induced Liver Injury - pathology ; Chemical and Drug Induced Liver Injury - prevention &amp; control ; Cytoprotection ; Disease Models, Animal ; Drug Administration Schedule ; Drug Tolerance ; Galactosamine ; Inflammation Mediators - metabolism ; Interleukin-1 Receptor-Associated Kinases - metabolism ; Lipopolysaccharides - administration &amp; dosage ; Lipopolysaccharides - toxicity ; Liver - drug effects ; Liver - immunology ; Liver - metabolism ; Liver - pathology ; Liver Failure, Acute - chemically induced ; Liver Failure, Acute - immunology ; Liver Failure, Acute - metabolism ; Liver Failure, Acute - pathology ; Liver Failure, Acute - prevention &amp; control ; Male ; Original ; Rats, Sprague-Dawley ; Signal Transduction - drug effects ; Time Factors ; Toll-Like Receptor 4 - genetics ; Toll-Like Receptor 4 - metabolism ; Transcription Factor RelA - metabolism</subject><ispartof>International journal of clinical and experimental pathology, 2014-01, Vol.7 (10), p.6626-6634</ispartof><rights>IJCEP Copyright © 2014 2014</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230075/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230075/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25400741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Sainan</creatorcontrib><creatorcontrib>Yang, Naibin</creatorcontrib><creatorcontrib>Ni, Shunlan</creatorcontrib><creatorcontrib>Li, Wenyuan</creatorcontrib><creatorcontrib>Xu, Lanman</creatorcontrib><creatorcontrib>Dong, Peihong</creatorcontrib><creatorcontrib>Lu, Mingqin</creatorcontrib><title>Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway</title><title>International journal of clinical and experimental pathology</title><addtitle>Int J Clin Exp Pathol</addtitle><description>Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to investigate the protecting mechanisms of endotoxin tolerance in acute liver failure induced by D-galactosamine (D-GalN)/LPS and possible role of toll-like receptors 4 (TLR4) signaling pathway in this phenomenon. Acute liver failure was induced by Injection of D-GalN/LPS. To mimic endotoxin tolerance, male Sprague-Dawley rats were treated with low dose of LPS (0.1 mg/kg once a day intraperitoneally for consecutive five days) before subsequent injection of D-GalN/LPS. Rat survival was determined by survival rate. Liver injury was confirmed by serum biochemical and liver histopathological examination. Inflammatory cytokines were determined by ELISA and nuclear factor-kappa B (NF-κB) (P65), toll-like receptors 4 (TLR4) and Interleukin-1 receptor-associated kinase-1 (IRAK-1) were measured by reverse transcriptase polymerase chain reaction and western blot respectively. Pretreatment of LPS significantly improved rat survival. Moreover, rats pretreated with LPS exhibited lower serum enzyme (ALT, AST and TBiL) level, lower production of inflammatory cytokines and more minor liver histopathological damage than rats without pretreatment of LPS. LPS pretreatment suppressed production of TLR4 and IRAK-1. LPS pretreatment also inhibited activation of hepatic NF-κB. These results indicated that endotoxin tolerance contributed to liver protection against D-GalN/LPS induced acute liver failure through down-regulation of TLR4 and NF-κB pathway.</description><subject>Animals</subject><subject>Chemical and Drug Induced Liver Injury - etiology</subject><subject>Chemical and Drug Induced Liver Injury - immunology</subject><subject>Chemical and Drug Induced Liver Injury - metabolism</subject><subject>Chemical and Drug Induced Liver Injury - pathology</subject><subject>Chemical and Drug Induced Liver Injury - prevention &amp; control</subject><subject>Cytoprotection</subject><subject>Disease Models, Animal</subject><subject>Drug Administration Schedule</subject><subject>Drug Tolerance</subject><subject>Galactosamine</subject><subject>Inflammation Mediators - metabolism</subject><subject>Interleukin-1 Receptor-Associated Kinases - metabolism</subject><subject>Lipopolysaccharides - administration &amp; dosage</subject><subject>Lipopolysaccharides - toxicity</subject><subject>Liver - drug effects</subject><subject>Liver - immunology</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Failure, Acute - chemically induced</subject><subject>Liver Failure, Acute - immunology</subject><subject>Liver Failure, Acute - metabolism</subject><subject>Liver Failure, Acute - pathology</subject><subject>Liver Failure, Acute - prevention &amp; control</subject><subject>Male</subject><subject>Original</subject><subject>Rats, Sprague-Dawley</subject><subject>Signal Transduction - drug effects</subject><subject>Time Factors</subject><subject>Toll-Like Receptor 4 - genetics</subject><subject>Toll-Like Receptor 4 - metabolism</subject><subject>Transcription Factor RelA - metabolism</subject><issn>1936-2625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVkFtLxDAQhYsgul7-guRRH4ppmqbdF0HWKyy66Ppcpsm0jaRNTdKV9ddb8II-DZyZ-Q7n7ESzZJ6KmAmW7UcH3r9SKhLG6V60zzJOac6TWfSxchgcQuiwD8TWxOjBDtZsPUjZgtMKyely9XxGoEOjrYOAnlzFt2Aezied6F6NEhUBOQacvjfoSA3ajA5JaJ0dm5asl0-ceN30YHTfkAFC-w7bo2i3BuPx-HseRi831-vFXbx8vL1fXC7jgQkR4gwyhYzniqUoZV7ReVVwJngllaoV5BSSlKcMKSuKLEtqqKigBVO0wCTLK0gPo4sv7jBWHSo5BXVgysHpDty2tKDL_5tet2VjNyVn6dRSNgFOvwHOvo3oQ9lpL9EY6NGOvkwEy2kuxHw-nZ789fo1-Sk8_QQYvn38</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Zhang, Sainan</creator><creator>Yang, Naibin</creator><creator>Ni, Shunlan</creator><creator>Li, Wenyuan</creator><creator>Xu, Lanman</creator><creator>Dong, Peihong</creator><creator>Lu, Mingqin</creator><general>e-Century Publishing Corporation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway</title><author>Zhang, Sainan ; Yang, Naibin ; Ni, Shunlan ; Li, Wenyuan ; Xu, Lanman ; Dong, Peihong ; Lu, Mingqin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-5a5de247d23ecc7b09b84264bcddfda70a13432e0288551fab06082d08e157ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Chemical and Drug Induced Liver Injury - etiology</topic><topic>Chemical and Drug Induced Liver Injury - immunology</topic><topic>Chemical and Drug Induced Liver Injury - metabolism</topic><topic>Chemical and Drug Induced Liver Injury - pathology</topic><topic>Chemical and Drug Induced Liver Injury - prevention &amp; control</topic><topic>Cytoprotection</topic><topic>Disease Models, Animal</topic><topic>Drug Administration Schedule</topic><topic>Drug Tolerance</topic><topic>Galactosamine</topic><topic>Inflammation Mediators - metabolism</topic><topic>Interleukin-1 Receptor-Associated Kinases - metabolism</topic><topic>Lipopolysaccharides - administration &amp; dosage</topic><topic>Lipopolysaccharides - toxicity</topic><topic>Liver - drug effects</topic><topic>Liver - immunology</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Failure, Acute - chemically induced</topic><topic>Liver Failure, Acute - immunology</topic><topic>Liver Failure, Acute - metabolism</topic><topic>Liver Failure, Acute - pathology</topic><topic>Liver Failure, Acute - prevention &amp; control</topic><topic>Male</topic><topic>Original</topic><topic>Rats, Sprague-Dawley</topic><topic>Signal Transduction - drug effects</topic><topic>Time Factors</topic><topic>Toll-Like Receptor 4 - genetics</topic><topic>Toll-Like Receptor 4 - metabolism</topic><topic>Transcription Factor RelA - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Sainan</creatorcontrib><creatorcontrib>Yang, Naibin</creatorcontrib><creatorcontrib>Ni, Shunlan</creatorcontrib><creatorcontrib>Li, Wenyuan</creatorcontrib><creatorcontrib>Xu, Lanman</creatorcontrib><creatorcontrib>Dong, Peihong</creatorcontrib><creatorcontrib>Lu, Mingqin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Sainan</au><au>Yang, Naibin</au><au>Ni, Shunlan</au><au>Li, Wenyuan</au><au>Xu, Lanman</au><au>Dong, Peihong</au><au>Lu, Mingqin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway</atitle><jtitle>International journal of clinical and experimental pathology</jtitle><addtitle>Int J Clin Exp Pathol</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>7</volume><issue>10</issue><spage>6626</spage><epage>6634</epage><pages>6626-6634</pages><eissn>1936-2625</eissn><abstract>Endotoxin tolerance (ET) is an important phenomenon, which affects inflammation and phagocytosis. Pretreatment with low dose of lipopolysaccharide (LPS) can protect liver injury from various hepatotoxicants such as acetaminophen and pseudomonas aeruginosa exotoxin A. The current study aimed to investigate the protecting mechanisms of endotoxin tolerance in acute liver failure induced by D-galactosamine (D-GalN)/LPS and possible role of toll-like receptors 4 (TLR4) signaling pathway in this phenomenon. Acute liver failure was induced by Injection of D-GalN/LPS. To mimic endotoxin tolerance, male Sprague-Dawley rats were treated with low dose of LPS (0.1 mg/kg once a day intraperitoneally for consecutive five days) before subsequent injection of D-GalN/LPS. Rat survival was determined by survival rate. Liver injury was confirmed by serum biochemical and liver histopathological examination. Inflammatory cytokines were determined by ELISA and nuclear factor-kappa B (NF-κB) (P65), toll-like receptors 4 (TLR4) and Interleukin-1 receptor-associated kinase-1 (IRAK-1) were measured by reverse transcriptase polymerase chain reaction and western blot respectively. Pretreatment of LPS significantly improved rat survival. Moreover, rats pretreated with LPS exhibited lower serum enzyme (ALT, AST and TBiL) level, lower production of inflammatory cytokines and more minor liver histopathological damage than rats without pretreatment of LPS. LPS pretreatment suppressed production of TLR4 and IRAK-1. LPS pretreatment also inhibited activation of hepatic NF-κB. These results indicated that endotoxin tolerance contributed to liver protection against D-GalN/LPS induced acute liver failure through down-regulation of TLR4 and NF-κB pathway.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>25400741</pmid><tpages>9</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1936-2625
ispartof International journal of clinical and experimental pathology, 2014-01, Vol.7 (10), p.6626-6634
issn 1936-2625
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230075
source PubMed Central Free
subjects Animals
Chemical and Drug Induced Liver Injury - etiology
Chemical and Drug Induced Liver Injury - immunology
Chemical and Drug Induced Liver Injury - metabolism
Chemical and Drug Induced Liver Injury - pathology
Chemical and Drug Induced Liver Injury - prevention & control
Cytoprotection
Disease Models, Animal
Drug Administration Schedule
Drug Tolerance
Galactosamine
Inflammation Mediators - metabolism
Interleukin-1 Receptor-Associated Kinases - metabolism
Lipopolysaccharides - administration & dosage
Lipopolysaccharides - toxicity
Liver - drug effects
Liver - immunology
Liver - metabolism
Liver - pathology
Liver Failure, Acute - chemically induced
Liver Failure, Acute - immunology
Liver Failure, Acute - metabolism
Liver Failure, Acute - pathology
Liver Failure, Acute - prevention & control
Male
Original
Rats, Sprague-Dawley
Signal Transduction - drug effects
Time Factors
Toll-Like Receptor 4 - genetics
Toll-Like Receptor 4 - metabolism
Transcription Factor RelA - metabolism
title Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A11%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20of%20lipopolysaccharide%20(LPS)%20ameliorates%20D-GalN/LPS%20induced%20acute%20liver%20failure%20through%20TLR4%20signaling%20pathway&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20pathology&rft.au=Zhang,%20Sainan&rft.date=2014-01-01&rft.volume=7&rft.issue=10&rft.spage=6626&rft.epage=6634&rft.pages=6626-6634&rft.eissn=1936-2625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1627076699%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p266t-5a5de247d23ecc7b09b84264bcddfda70a13432e0288551fab06082d08e157ba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1627076699&rft_id=info:pmid/25400741&rfr_iscdi=true